Sitavia 50 mg (Sitagliptin Phosphate)

Adult dose

This medication is administered once daily at a dose of 100 mg, with a maximum daily dose of 100 mg. In patients with renal impairment, dosage adjustment may be required. - Mild renal impairment (eGFR 60 < 90): No dosage adjustment required. - Moderate renal impairment (eGFR 45 < 60): No dosage adjustment required. - Moderate renal impairment (eGFR 30 < 45): 50 mg once daily.

This medication may cause severe allergic reactions after administration, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, usage should be discontinued immediately and medical consultation should be sought. During the usage of this medication, serious inflammation of the pancreas known as pancreatitis may occur; hence, if symptoms like abdominal pain, nausea, or vomiting arise, healthcare personnel must be notified immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients allergic to this medication or its components. Patients with decreased kidney function may have slower elimination of the drug, making it important to adjust the dosage or use caution, and regular kidney function tests are essential. Clinical trial results indicate that common side effects when this medication is used alone or in combination with other diabetes medications include upper respiratory infections, headaches, nasopharyngitis, and diarrhea, especially when taken with insulin or sulfonylureas, which may increase the risk of hypoglycemia. If hypoglycemic symptoms occur while taking the medication, blood sugar should be checked immediately, and appropriate action should be taken if necessary, and dose adjustment of insulin or sulfonylureas may be needed. This medication is not recommended for use during pregnancy, and it is also advisable for breastfeeding women to avoid taking it. The safety and efficacy in children and adolescents have not been established, hence it should not be used by individuals under 18 years old. For elderly patients, the risk of decreased kidney function is higher, so dosage adjustment and kidney function monitoring are necessary. In case of overdose, general emergency treatment should be provided, and if necessary, hemodialysis can be performed to remove the drug from the system. While drug interactions with this medication are minimal, changes in blood concentration may occur when used with certain drugs, so consultation with a physician or pharmacist is advised. If severe joint pain or blistering skin occurs during medication use, immediate medical evaluation is required, and if symptoms are severe, the administration of the drug may need to be discontinued. This medication has not reported significant cardiovascular safety issues even with long-term use; however, regular health checkups are recommended.

Serious side effects

Anaphylaxis, angioedema, urticaria, severe edema, rash, Stevens-Johnson syndrome, cutaneous vasculitis, exfoliative dermatitis, acute pancreatitis, liver abnormalities due to elevated liver enzymes (including jaundice), acute renal failure, severe and disabling joint pain, bullous pemphigoid, rhabdomyolysis, pneumonia, diabetes complications, metabolic acidosis, cardiac arrest

Mild side effects

• Headache
• upper respiratory infection
• nasopharyngitis
• constipation
• vomiting
• muscle pain
• limb pain
• back pain
• itching
• thrombocytopenia

This medication should be stored in a tightly sealed container to prevent air exposure and is best kept at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.

Appearance

Bright beige, convex, round film-coated tablet

Package unit

30 tablets (10 tablets/PTPX3)